Dental management of patients at risk of osteochemonecrosis of the jaws: a critical review

被引:30
作者
Fedele, S. [1 ]
Kumar, N. [2 ]
Davies, R. [2 ]
Fiske, J. [3 ]
Greening, S. [4 ]
Porter, S. [1 ]
机构
[1] UCL, Eastman Dent Inst, Oral Med & Special Care Dent Unit, London WC1X 8LD, England
[2] UCLH, Eastman Dent Hosp, London, England
[3] Kings Coll London, Inst Dent, Dept Sedat & Special Care Dent, London, England
[4] Gwent Healthcare NHS Trust, Wales DCDP Kings, Newport, Gwent, Wales
关键词
bone and joints; anatomic site; oncology; discipline; infectious diseases; pathogenesis; wound healing; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS; ORAL BISPHOSPHONATES; MULTIPLE-MYELOMA; SERUM CTX; UPDATED RECOMMENDATIONS; PREVENTIVE MEASURES; ZOLEDRONIC ACID; BONE METASTASES; CANCER-PATIENTS; OSTEOPOROSIS;
D O I
10.1111/j.1601-0825.2009.01581.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Osteonecrosis of the jaw bones is a complication of bisphosphonate (BP) drug usage characterised by trans-mucosal exposure of necrotic bone, often followed by infection and pain. Osteonecrosis is observed in cancer patients on high-potency intravenous BP more frequently than in osteoporotic individuals using low-potency oral BP. The management of osteonecrosis caused by BP is often unsatisfactory and control of risk factors is considered the most effective means of prevention. Surgical manipulation and dental infection of the jawbone are the major risk factors, hence it is suggested that careful management of oral health and relevant dental procedures may decrease the risk of osteonecrosis in individuals on BP. Recommendations for dentists and oral surgeons have been suggested by different groups of clinicians but they are often controversial and there is no clear evidence for their efficacy in reducing the likelihood of osteonecrosis development. This report critically reviews current dental recommendations for individuals using BP with the aim of helping the reader to transfer them into practice as part of pragmatic and non-detrimental clinical decisions making.
引用
收藏
页码:527 / 537
页数:11
相关论文
共 61 条
[2]   Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells [J].
Allegra, A. ;
Oteri, G. ;
Nastro, E. ;
Alonci, A. ;
Bellomo, G. ;
Del Fabro, V. ;
Quartarone, E. ;
Alati, C. ;
De Ponte, F. S. ;
Cicciu, D. ;
Musolino, C. .
HEMATOLOGICAL ONCOLOGY, 2007, 25 (04) :164-169
[3]   STATISTICS NOTES - ABSENCE OF EVIDENCE IS NOT EVIDENCE OF ABSENCE [J].
ALTMAN, DG ;
BLAND, JM .
BRITISH MEDICAL JOURNAL, 1995, 311 (7003) :485-485
[4]   Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates [J].
Bagan, Jose V. ;
Jimenez, Yolanda ;
Gomez, Dolores ;
Sirera, Rafael ;
Poveda, Rafael ;
Scully, Crispian .
ORAL ONCOLOGY, 2008, 44 (11) :1088-1089
[5]  
Baim S, 2009, J BONE MINER RES, V24, P561, DOI [10.1359/JBMR.090203, 10.1359/jbmr.090203]
[6]   Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].
Bamias, A ;
Kastritis, E ;
Bamia, C ;
Moulopoulos, LA ;
Melakopoulos, L ;
Bozas, G ;
Koutsoukou, V ;
Gika, D ;
Anagnostopoulos, A ;
Papadimitriou, C ;
Terpos, E ;
Dimopoulos, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587
[7]   Survey of members of myeloma UK on biphosphonates-associated jaw osteonecrosis [J].
Barker, Kate ;
Lowe, Derek ;
Olujohungbe, Ade ;
Low, Eric ;
Rogers, Simon N. .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (04) :626-628
[8]   Oral Bisphosphonates and dental implants: A retrospective study [J].
Bell, Brian M. ;
Bell, Robert Edward .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2008, 66 (05) :1022-1024
[9]  
Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO
[10]  
2-0